Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Canadian Cancer)"
Count: 339
Selected: 0
| NCT ID | Title |
|---|
| NCT03624543 | CFI-400945 in Patients With Advanced/Metastatic Breast Cancer | ||
| NCT03385655 | Prostate Cancer Biomarker Enrichment and Treatment Selection | ||
| NCT03784755 | Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer | ||
| NCT04224974 | Emotion and Symptom-Focused Engagement Trial for Individuals With Acute Leukemia | ||
| NCT04442048 | Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure | ||
| NCT03568422 | CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer | ||
| NCT02821013 | Duration of Anti-PD-1 Therapy in Metastatic Melanoma | ||
| NCT00482677 | Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme | ||
| NCT04663997 | 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer | ||
| NCT03550391 | Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases | ||
| NCT02719977 | A Phase I Study of CX5461 | ||
| NCT04093167 | Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With NSCLC | ||
| NCT02033993 | Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen. | ||
| NCT02512965 | Study Comparing Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy (CRT) for Spinal Metastases | ||
| NCT00993655 | Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer | ||
| NCT00754845 | Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy | ||
| NCT02784171 | Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma | ||
| NCT01101438 | A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer | ||
| NCT04918186 | Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer | ||
| NCT03461952 | Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) | ||
| NCT05371808 | Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: | ||
| NCT05451004 | SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer | ||
| NCT03488693 | Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | ||
| NCT02597062 | High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma | ||
| NCT01658930 | Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer | ||
| NCT02273375 | Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC | ||
| NCT05180097 | Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | ||
| NCT04650581 | Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor | ||
| NCT04176848 | CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer | ||
| NCT04161248 | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | ||
| NCT03847649 | A Phase II Study of Durvalumab | ||
| NCT03822897 | De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma | ||
| NCT03768570 | Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer | ||
| NCT03480776 | ASA in Prevention of Ovarian Cancer (STICs and STONEs) | ||
| NCT03410615 | Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC | ||
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | ||
| NCT03259035 | NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer | ||
| NCT03057106 | Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC | ||
| NCT02974803 | Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases | ||
| NCT02960087 | Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer | ||
| NCT02905318 | Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer | ||
| NCT02879318 | Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma | ||
| NCT02879162 | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | ||
| NCT02870920 | Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer | ||
| NCT02788773 | Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer | ||
| NCT02740920 | Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker | ||
| NCT02649686 | Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab | ||
| NCT02630693 | Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer | ||
| NCT02619864 | mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme | ||
| NCT02537418 | Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens |
